Clinical data presentation of KEYTRUDA® (pembrolizumab) in combination with chemotherapy in eligible PD-L1-negative mNSCLC patients
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Could KEYTRUDA in combination with chemotherapy improve treatment expectations for untreated squamous and non-squamous PD-L1 mNSCLC patients?*†
*KEYTRUDA, in combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.1
†KEYTRUDA, in combination with carboplatin and either paclitaxel or nab-paclitaxel, is indicated for the first-line treatment of metastatic squamous NSCLC in adults.1
ALK = Anaplastic Lymphoma Kinase; EGFR = Epidermal Growth Factor Receptor; NSCLC = Non-Small Cell Lung Cancer; PD-L1 = Programmed Cell Death Ligand 1.
Find out more information about KEYTRUDA® (pembrolizumab) in metastatic NSCLC:
- KEYTRUDA Summary of Product Characteristics.
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website